-DR/

Lebanon

Population 2010 (milli	ons) 4	
Estimates of burden * 2010	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	0.09 (0.063-0.12)	2.1 (1.5–2.9)
Prevalence (incl HIV)	1 (0.45–1.7)	24 (11–39)
Incidence (incl HIV)	0.72 (0.63–0.83)	17 (15–20)
Incidence (HIV-positive)	0.059 (0.034–0.089)	1.4 (0.81–2.1)
Case detection, all forms (%)	71 (62–81)	


Case notifications 2010				
New cases		(%) Retreatment cases		(%)
Smear-positive	194	(39) Relapse	10	(83)
Smear-negative	99	(20) Treatment after failure	2	(17)
Smear unknown	0	(0) Treatment after default	0	(0)
Extrapulmonary	210	(42) Other	0	(0)
Other	0	(0)		
Total new	503	Total retreatment	12	
Total < 15 years	43			

Total new and relapse	513	(100% of total)
Total cases notified	515	

Drug regimens	
Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	100
Paediatric formulations procured	Yes

Treatment success rate 2009 (%)	
New smear-positive	82
New smear-negative/extrapulmonary	87
Retreatment	80

Treatment success rate (%)




MDR-TB, Estimates among notified cases *	
% of new TB cases with MDR-TB	1.1 (0.10–3.8)
% of retreatment TB cases with MDR-TB	36 (13–65)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	3.2 (0.29–11)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	4.3 (1.5–7.8)


MDR-TB reported cases 2010	New	Retreat- ment	Total
Cases tested for MDR-TB	4	14	18
% of notified tested for MDR-TB	<1	117	3
Confirmed cases of MDR-TB	2	5	7
MDR-TB patients started treatment			7
Laboratories	2009	2010	2011
Smear (per 100 000 population)	4.0	3.9	3.9
Culture (per 5 million population)	3.6	3.5	3.5
DST (per 5 million population)	1.2	1.2	1.2



Incidence (HIV+TB in orange), notifications (black) (rates per 100 000 population)




Prevalence (rate per 100 000 population)



Mortality excluding HIV

(rate per 100 000 population)



TB/HIV 2010

ID/	1110 201	0					
ΤВ	patients	with kno	wn HIV s	status			
% o	of TB pat	ients wit	h known	HIV statu	JS		
TΒ	patients	that are	HIV-posi	tive			
% o	of tested	TB patie	nts that a	are HIV-p	ositive		
%⊦	HV-posit	ive TB p	atients st	arted on	CPT		
%⊦	HV-posit	ive TB p	atients st	arted on	ART		
HIV	'-positive	e people	screened	for TB			
HIV	'-positive	e people	provided	with IPT			
CPT	Г (orang	e) and A	RT (gree	n) for HI	/-positive	e TB patie	ents (
30							
							\checkmark
20							
10							
0			_				
۳L			_				

Financing	2011
Total budget (US\$ millions)	<1
Available funding (US\$ millions)	<1
% of budget funded	98
% available funding from domestic sources	98
% available funding from Global Fund	0
	(1.10.0

NTP Budget (blue) and available funding (green) (US\$ millior



* Ranges represent uncertainty intervals

Generated: August 28, 2011